Oppenheimer & Co’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.15M Sell
11,330
-40
-0.4% -$7.52K 0.02% 622
2026
Q1
$2.24M Buy
+11,370
New +$2.19M 0.03% 553
2025
Q4
Sell
-14,869
Closed -$2.28M 1577
2025
Q3
$2.28M Buy
14,869
+1,028
+7% +$156K 0.03% 560
2025
Q2
$1.93M Buy
13,841
+1,938
+16% +$272K 0.03% 585
2025
Q1
$1.75M Sell
11,903
-60
-0.5% -$8.68K 0.03% 583
2024
Q4
$1.57M Buy
11,963
+681
+6% +$95.3K 0.02% 630
2024
Q3
$1.76M Buy
11,282
+2,999
+36% +$484K 0.03% 597
2024
Q2
$1.29M Sell
8,283
-851
-9% -$128K 0.02% 675
2024
Q1
$1.24M Buy
9,134
+847
+10% +$112K 0.02% 664
2023
Q4
$1.12M Buy
8,287
+1,075
+15% +$140K 0.02% 671
2023
Q3
$977K Buy
7,212
+2,459
+52% +$336K 0.02% 685
2023
Q2
$680K Sell
4,753
-458
-9% -$67.4K 0.01% 859
2023
Q1
$723K Sell
5,211
-382
-7% -$51.4K 0.02% 811
2022
Q4
$758K Buy
5,593
+83
+2% +$10.4K 0.02% 772
2022
Q3
$604K Sell
5,510
-1,912
-26% -$243K 0.01% 823
2022
Q2
$980K Buy
7,422
+1,121
+18% +$147K 0.02% 691
2022
Q1
$836K Buy
6,301
+101
+2% +$12.1K 0.02% 811
2021
Q4
$722K Buy
6,200
+148
+2% +$17.4K 0.01% 905
2021
Q3
$727K Sell
6,052
-1,221
-17% -$142K 0.01% 865
2021
Q2
$872K Sell
7,273
-5,120
-41% -$562K 0.02% 804
2021
Q1
$1.23M Buy
12,393
+20
+0.2% +$2.01K 0.02% 638
2020
Q4
$1.24M Sell
12,373
-1,697
-12% -$180K 0.03% 577
2020
Q3
$1.54M Buy
14,070
+6,801
+94% +$756K 0.04% 451
2020
Q2
$768K Buy
7,269
+3,143
+76% +$325K 0.02% 673
2020
Q1
$368K Sell
4,126
-8,109
-66% -$763K 0.01% 835
2019
Q4
$1.22M Sell
12,235
-1,073
-8% -$101K 0.03% 556
2019
Q3
$1.19M Sell
13,308
-169
-1% -$14.7K 0.03% 542
2019
Q2
$1.11M Sell
13,477
-527
-4% -$41.3K 0.03% 559
2019
Q1
$1.13M Buy
14,004
+223
+2% +$17.6K 0.03% 555
2018
Q4
$1.05M Sell
13,781
-4,672
-25% -$365K 0.03% 525
2018
Q3
$1.46M Sell
18,453
-363
-2% -$27.5K 0.04% 482
2018
Q2
$1.32M Buy
18,816
+647
+4% +$46.5K 0.04% 499
2018
Q1
$1.27M Buy
18,169
+3,428
+23% +$237K 0.03% 528
2017
Q4
$1.02M Buy
14,741
+6,634
+82% +$447K 0.03% 606
2017
Q3
$550K Buy
8,107
+1,205
+17% +$76.1K 0.01% 813
2017
Q2
$470K Sell
6,902
-2,601
-27% -$170K 0.01% 851
2017
Q1
$592K Buy
9,503
+4,626
+95% +$269K 0.02% 741
2016
Q4
$267K Sell
4,877
-14,859
-75% -$844K 0.01% 1046
2016
Q3
$1.3M Buy
19,736
+4,745
+32% +$310K 0.04% 502
2016
Q2
$906K Buy
14,991
+7,877
+111% +$458K 0.03% 577
2016
Q1
$400K Buy
7,114
+317
+5% +$19K 0.01% 833
2015
Q4
$462K Sell
6,797
-912
-12% -$59.8K 0.01% 788
2015
Q3
$491K Buy
7,709
+2,443
+46% +$161K 0.01% 813
2015
Q2
$336K Sell
5,266
-220
-4% -$15.1K 0.01% 1051
2015
Q1
$376K Buy
5,486
+327
+6% +$22.7K 0.01% 1008
2014
Q4
$363K Sell
5,159
-366
-7% -$26.2K 0.01% 953
2014
Q3
$395K Sell
5,525
-15,918
-74% -$1.17M 0.01% 944
2014
Q2
$1.59M Sell
21,443
-9,551
-31% -$690K 0.05% 444
2014
Q1
$2.01M Sell
30,994
-4,460
-13% -$288K 0.06% 378
2013
Q4
$2.1M Sell
35,454
-10,408
-23% -$565K 0.07% 340
2013
Q3
$2.38M Buy
45,862
+4,140
+10% +$208K 0.08% 291
2013
Q2
$1.97M Buy
+41,722
New +$2.12M 0.08% 310

Other funds holding AZN

Oppenheimer & Co's AZN Position: Q2 2026 in Review

Oppenheimer & Co reduced its AstraZeneca (AZN) stake by 0.35% in Q2 2026, selling an estimated $7.52K and leaving 11,330 shares worth $2.15M. The position accounts for 0.02% of the portfolio, ranked #622.

Oppenheimer & Co first reported a position in AZN in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.38M in Q3 2013. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Oppenheimer & Co held 11,330 shares of AstraZeneca worth $2.15M as of Q2 2026.
  • Oppenheimer & Co sold 40 AstraZeneca shares in Q2 2026, an estimated $7.52K.
  • AstraZeneca made up 0.02% of Oppenheimer & Co's portfolio in Q2 2026, its #622 holding.
  • Oppenheimer & Co first reported a position in AstraZeneca in Q2 2013 and has held it in 52 quarters since.
  • Oppenheimer & Co's AstraZeneca position peaked at $2.38M in Q3 2013.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.